Biotheranostics Announces Inclusion of Breast Cancer Index in the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines for Prediction of Benefit from Extended Endocrine Therapy
19. Januar 2021 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Breast Cancer Index™ (BCI) has reached an incredible milestone as a new standard of care to predict benefit from extended endocrine therapy for...
UPDATE - Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Consultant for Breast Oncology
29. Dezember 2020 18:15 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as a Chief Medical Consultant for Breast Oncology for Biotheranostics. Dr. Pegram is a key leader in...
Breast Cancer Index™ demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
17. Dezember 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit irrespective of clinical risk for HR+ early-stage...
Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020
08. Dezember 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held...
Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology
03. Dezember 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces Mark D. Pegram, MD as Chief Medical Advisor of Breast Oncology in support of Breast Cancer Index, the only commercially...
Biotheranostics’ Breast Cancer Index IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
29. Oktober 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of results from the IDEAL study in Clinical Cancer Research which reports novel findings of the Breast...
Biotheranostics CancerTYPE ID aids in patient selection for immunotherapy
21. September 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces the publication of a new study evaluating CancerTYPE ID® and its role in identifying subsets of patients with Cancer of...
Biotheranostics to Present at the LifeSci Partners Summer Symposium
27. Juli 2020 09:00 ET
|
Biotheranostics, Inc.
San Diego, CA, July 27, 2020 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., a leading healthcare provider in the oncology field with a suite of commercially available proprietary molecular diagnostic...
Biotheranostics presents new studies of the Breast Cancer Index® at the 2020 ASCO conference, expanding its clinical utility as a predictive tool for hormone receptor positive, early-stage breast cancer
29. Mai 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, May 29, 2020 (GLOBE NEWSWIRE) -- Biotheranostics announces several new studies demonstrating comprehensive validation and clinical utility of its Breast Cancer Index genomic assay for...
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
15. Mai 2020 08:00 ET
|
Biotheranostics, Inc.
San Diego, CA, May 15, 2020 (GLOBE NEWSWIRE) -- Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups of HR+ early stage...